Author | Matthew Farren, PhD | OncLive

Author | Matthew Farren, PhD

Articles

Findings for Pembrolizumab Plus mFOLFOX6 in Advanced CRC

January 09, 2019

Video

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).

Rationale for Pembrolizumab Plus mFOLFOX6 in Advanced CRC

November 15, 2018

Article

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.

x